Amgen and AbbVie agree to settlement allowing commercialization of Humira biosimilar

September 29, 2017 12:43 PM

amgen-abbvie-logo-biosimilarnews-biosimilar-news

Amgen announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding Amgevita/Amjevita, a biosimilar to AbbVie’s Humira (adalimumab). 

Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of Amgevita/Amjevita worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch Amgevita in Europe on October 16, 2018, and Amjevita in the United States on January 31, 2023.

“We look forward to leveraging our existing biologics capabilities to bring high-quality biosimilars to patients worldwide. Amgevita will be one of our first biosimilar launches, and this agreement will allow us to secure a strong foothold in the $4 billion European adalimumab market,” said Scott Foraker, vice president and general manager of Biosimilars at Amgen. “Building on our strong inflammatory disease presence in the United States, we are excited to develop our inflammation capabilities in Europe, extending our reach and helping more patients gain access to this important class of therapies.”

Specific financial terms of the agreement were not disclosed.

Source: Amgen

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!